Glaxosmithkline Share Price (GSK)

Show Chart Filters
Time period:
Moving Average:
Compare to:
Price 1,438.00on 05-08-2021 at 8:00:10
Change 4.40 0.31%
Buy 1,218.60
Sell 1,648.60
Buy / Sell GSK Shares
Sponsored Financial Content
Last Trade: Buy 3,637 at 1,436.47p
Day's Volume: 0
Last Close: 1,433.60p
Open: 1,440.00p
ISIN: GB0009252882
Day's Range 1,430.20p - 1,441.20p
52wk Range: 1,190.80p - 1,619.20p
Market Capitalisation: £72,135m
VWAP: 0.00p
Shares in Issue: 5,032m

Recent Trades History Glaxosmithkline (GSK)

Buy/Sell Volume Trade Prc Trade Type Trade Time
18:28:34 - 04-Aug-21
17:43:21 - 04-Aug-21
17:45:51 - 04-Aug-21
17:34:50 - 04-Aug-21
17:34:50 - 04-Aug-21
17:17:13 - 04-Aug-21
17:26:57 - 04-Aug-21
17:23:55 - 04-Aug-21
17:14:59 - 04-Aug-21
17:04:14 - 04-Aug-21

Share Price History for Glaxosmithkline

Time period:
Date Open High Low Close
2nd Aug 2021 (Mon)1,421.401,427.601,406.401,424.70
30th Jul 2021 (Fri)1,405.601,420.801,398.401,410.50
29th Jul 2021 (Thu)1,409.801,424.801,401.801,410.50
28th Jul 2021 (Wed)1,389.001,426.201,383.401,397.60
27th Jul 2021 (Tue)1,392.801,401.801,383.601,397.60
26th Jul 2021 (Mon)1,411.201,415.601,393.201,397.30
23rd Jul 2021 (Fri)1,408.601,419.201,406.401,417.90
22nd Jul 2021 (Thu)1,411.801,416.001,402.801,409.40
21st Jul 2021 (Wed)1,411.601,432.001,408.601,413.70
20th Jul 2021 (Tue)1,421.401,425.201,409.001,413.10
19th Jul 2021 (Mon)1,424.401,441.001,401.601,413.10
16th Jul 2021 (Fri)1,411.801,424.601,407.801,422.10
15th Jul 2021 (Thu)1,437.801,439.001,406.801,409.50
14th Jul 2021 (Wed)1,438.601,441.401,427.801,441.20
13th Jul 2021 (Tue)1,433.201,444.201,430.001,443.10
12th Jul 2021 (Mon)1,428.201,441.801,418.601,439.10
9th Jul 2021 (Fri)1,431.801,440.201,425.001,432.80
8th Jul 2021 (Thu)1,430.001,432.401,417.201,424.50
7th Jul 2021 (Wed)1,435.201,438.601,426.401,439.10
6th Jul 2021 (Tue)1,429.001,440.001,426.801,431.20
5th Jul 2021 (Mon)1,441.601,444.001,427.601,433.60

GSK - Glaxosmithkline Investor Summary

GlaxoSmithKline, or 'GSK', is one of the world's leading pharmaceutical companies researching medicines and vacines alike for the World Health Organization's three priority diseases: HIV/AIDS, Malaria and Tuberculosis. With an estimated 7% of the world's pharmaceutical market under its wing, GSK remains one of the industry leaders globally but remains committed to the research and application of life changing and marketable drugs.

If investing in science seems a little confusing and unpredictable then perhaps some of GSK's over-the-counter and more recognisable products will help to convince; these include Gaviscon and Panadol, smoking control products such as Nicorette/Niquitin and nutritional healthcare drinks such as Lucozade, Ribena and Horlicks.

On 23rd January 2009, GSK announced that it had signed an agreement with UCB S.A to acquire its marketed product portfolio in certain parts of the Middle East, Africa, Latin America and Asia Pacific, for a cash consideration of some £484 million. President of Emerging Markets at GSK, Abbas Hussain, said that "This acquisition will strengthen and expand GSK's product portfolio in these countries, helping us to meet the needs of patients, particularly in the areas of epilepsy and respiratory." Under the agreement, GSK acquires several leading pharmaceutical brands and investors will be interested to know that the commercial operations and product distribution rights included represent approximately 3-4% of UCB's 2008 expected revenue of at least £3.09 billion. At the time of Mr Hussain speaking, share prices for GSK were steady at 1,226.00p with a "strong buy" recommendation from brokers.

News about Glaxosmithkline (GSK)

Director Deals - (GSK)

News - Tuesday, July 27, 2021

Hal Barron, Executive Director, bought 2,361 shares in the company on the 22nd J......

Director Deals - (GSK)

News - Monday, July 19, 2021

Emma Walmsley, Director, has re-invested 2,800 shares in the company on the 13th......

FTSE 100 Latest

Login to your account

Forgot Password?

Not Registered